FRONTAGE (01521) released its annual performance with a net profit attributable to shareholders of $6.793 million, a year-on-year increase of 758.8%.

FRONTAGE (01521) announced the annual performance for the year ending December 31, 2025. The group achieved a revenue of $257 million, an increase of 0.7% compared to the previous year. The profit attributable to owners of the company was $6.793 million, an increase of 758.8%, with a basic earnings per share of $0.0034. The announcement stated that revenue from North America and Europe businesses slightly decreased, mainly due to a decline in revenue from drug discovery business. This was a result of the negative impact of pharmaceutical and biotechnology companies continuing to optimize their research and development portfolio and prudently control development expenses. However, the strong demand for laboratory testing services partially offset this decline. The revenue growth in China business was mainly due to the improvement in capacity utilization and the group's marketing efforts.